Results 151 to 160 of about 3,353 (184)

Molecular Basis of Class A β-Lactamase Inhibition by Relebactam [PDF]

Antimicrobial Agents and Chemotherapy, 2019
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are required.
Philip Hinchliffe, Jürgen Brem, Christopher Schofield   +2 more
exaly   +8 more sources

Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
The imipenem-relebactam combination is in development as a potential treatment regimen for infections caused by Enterobacteriaceae possessing complex β-lactamase backgrounds.
Robert Bonomo, Krisztina Papp-Wallace
exaly   +2 more sources

Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram‐Negative Bacterial Infections: A Phase 1b, Open‐Label, Single‐Dose Clinical Trial [PDF]

Journal of Clinical Pharmacology, 2023
Imipenem/cilastatin/relebactam is approved for the treatment of serious gram-negative bacterial infections in adults. This study assessed the pharmacokinetics (PK), safety, and tolerability of a single dose of imipenem/cilastatin/relebactam (with a fixed
Amanda Paschke, Munjal Patel
exaly   +3 more sources

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2018
This phase I study assessed the intrapulmonary pharmacokinetic profiles of relebactam (MK-7655), a novel β-lactamase inhibitor, and imipenem. Sixteen healthy subjects received 250 mg relebactam with 500 mg imipenem-cilastatin, given intravenously every 6
Elizabeth Rhee, Sheng Bi, Mark H Gotfried   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales

Clinical Microbiology and Infection, 2023
The treatment options for infections caused by carbapenem-resistant Enterobacterales are scarce and the development of new antibiotics is an urgent necessity. Imipenem/relebactam (IPR) has been recently introduced for treating severe infections related to multidrug-resistant bacteria.
Maxime, Bouvier, Otávio Hallal Ferreira, Raro, Auriane, Kerbol, Laurent, Poirel, Patrice, Nordmann   +4 more
openaire   +2 more sources

In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates

International Journal of Antimicrobial Agents, 2023
Mycobacterium abscessus is an emerging infection in people living with lung diseases, including cystic fibrosis (CF) and bronchiectasis, and it has limited treatment options and low cure rates. The off-label use of novel antibiotics developed for other bacterial pathogens offers potential new therapeutic options.
Jason Roberts, Scott Bell
exaly   +5 more sources

Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections

Expert Opinion on Pharmacotherapy, 2020
The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens.
S.G. Kuiper, E. Leegwater, E.B. Wilms, C. van Nieuwkoop   +3 more
openaire   +2 more sources

Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy

Clinical Pharmacokinetics, 2020
On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections. This decision was based on substantial clinical and pre-clinical data, including rigorous pharmacokinetic and pharmacodynamic work ...
openaire   +2 more sources

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

Clinical Pharmacology in Drug Development, 2020
AbstractThe effects of supratherapeutic doses of intravenous (IV) relebactam on duration of ventricular depolarization and subsequent repolarization were assessed in a thorough QT/corrected QT study. This was a single‐dose, double‐blind (relebactam only), randomized, placebo‐ and positive‐controlled, 3‐period, balanced crossover study in healthy ...
Keith, Boundy, Yang, Liu, Pratik, Bhagunde, Terry E, O'Reilly, Francheska, Colon-Gonzalez, Evan J, Friedman, Mallika, Lala, Elizabeth G, Rhee, Matthew L, Rizk   +8 more
openaire   +2 more sources